About this trial
P-CCROSS is a randomized, prospective monocentric phase 4 study with a crossover study design. The aim of the study is to compare patient satisfaction (by means of questionnaires) and treatment compliance with IVF treatment with CFA (corifollitropin alfa) and PPOS (Progestin-Primed Ovarian Stimulation) versus conventional IVF treatment with a recombinant FSH/GnRH antagonist. The study will also compare patients undergoing elective fertility preservation versus PGT-A (pre-implantation genetic testing for aneuploidy) patients.The study will have a crossover design so that patients will receive both forms of treatment. The investigators will also compare the endocrine profile and ovarian response of CFA/PPOS versus rFSH/GnRH ovarian stimulation cycles.
Eligibility criteria
Qualifiers
Group 1: indication for oocyte cryopreservation
Group 2: indication for IVF/ICSI and PGT-A
First ovarian stimulation cycle
Aged ≥ 18 and < 41 years old at the time of first OPU
Disqualifiers
contra-indication for ovarian stimulation
expected poor ovarian response (Bologna Criteria)
PCOS patients
refusal to fill out questionnaires before, during and after treatment
Trial design
Treatments tested in this trial
- Elonva®
- Puregon®
- Orgalutran®
- Gonapeptyl®
- Cerazette®
Treatment groups
Sponsors and collaborators
University Hospital, Ghent
Lead sponsor
Organon
Collaborator